While a number of topical products designed to reduce the occurrence of sexually transmitted infections have been tested with largely disappointing results, researchers at Boston University School of Medicine (BUSM), Alpert Medical School of Brown University and Mapp Biopharmaceutical have now found that MB66, a vaginal film product containing monoclonal antibodies against human immunodeficiency virus-type 1 (HIV-1) and herpes simplex viruses types 1 and 2 (HSV-1 and 2), is safe and effective.